Cadila Healthcare’s subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, has settled the patent litigation relating to Aptalis’s CANASA (mesalamine suppository, 1 g). As a result of the settlement, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of CANASA in the United States beginning on June 13, 2019, or earlier under certain circumstances.
Zydus Cadila previously received tentative approval from the USFDA to market its generic version of CANASA (mesalamine suppository, 1 g). CANASA is indicated to treat mildly to moderately active ulcerative colitis. Zydus Cadila’s generic product will be produced at the group’s Topical plant at Ahmedabad.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
